Global Hereditary Angioedema Therapeutics Market 2018-2022 | Emergence of Innovative Treatment Strategies | Technavio
LONDON--(BUSINESS WIRE)--Sep 18, 2018--The global hereditary angioedema therapeutics market 2018-2022 is expected to post a CAGR of close to 9% during the forecast period, according to the latest market research report by .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005944/en/
Technavio has published a new market research report on the global hereditary angioedema therapeutics market for the period 2018-2022. (Graphic: Business Wire)
A key factor driving the growth of the market is the increasing prevalence of hereditary angioedema. The rising cases of hereditary angioedema are increasing the possibility of transmission of the disease to the future generation. Therefore, it is expected that the distribution of the disease and the demand for therapeutics will increase during the coming years, which, in turn, results in the growth of the global hereditary angioedema therapeutics market.
This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
In this report, Technavio highlights the emergence of innovative treatment strategies as one of the key emerging trends in the global hereditary angioedema therapeutics market:
Global hereditary angioedema therapeutics market: Emergence of innovative treatment strategies
The main challenge of the high cost of treatment can be resolved with the help of self-administration of the therapeutics. Self-administration reduces cost by reducing the frequent visits to hospitals. Several pharmaceutical companies are taking various initiatives to make patients aware of the treatment and procedure.
“For instance, Shire has organized a self-administration training under “The Path to independence” program. This program provides training about the administration of CINRYZE by specialized nurses. This program includes training related to storage, handling, and disrupting of CINRYZE. Such instances help patients to get the disease diagnosed and treated before it gets complex,” says a senior analyst at Technavio.
Global hereditary angioedema therapeutics market: Segmentation analysis
This market research report segments the global hereditary angioedema therapeutics market by product (C1 inhibitors, icatibant, ecallantide, and others) and geographical regions (APAC, EMEA, and the Americas).
The Americas led the market in 2017 with a market share of close to 42%, followed by APAC and EMEA respectively. The region is expected to continue to dominate the market during the forecast period.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005944/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA SOUTH AMERICA AFRICA MIDDLE EAST
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES RESEARCH SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 09/18/2018 01:24 PM/DISC: 09/18/2018 01:24 PM